The Clinical Significance of Asymmetric Dimethylarginine
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
▪ Abstract In 1992, asymmetrical dimethylarginine (ADMA) was first described as an endogenous inhibitor of the arginine-nitric oxide (NO) pathway. From then, its role in regulating NO production has attracted increasing attention. Nowadays, ADMA is regarded as a novel cardiovascular risk factor. The role of the kidney and the liver in the metabolism of ADMA has been extensively studied and both organs have proven to play a key role in the elimination of ADMA. Although the liver removes ADMA exclusively via degradation by the enzyme dimethylarginine dimethylaminohydrolase (DDAH), the kidney uses both metabolic degradation via DDAH and urinary excretion to eliminate ADMA. Modulating activity and/or expression of DDAH is still under research and may be a potential therapeutic approach to influence ADMA plasma levels. Interestingly, next to its association with cardiovascular disease, ADMA also seems to play a role in other clinical conditions, such as critical illness, hepatic failure, and preeclampsia. To elucidate the clinical significance of ADMA in these conditions, the field of research must be enlarged.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
Leone, A., Moncada, S., Vallance, P., Calver, A., & Collier, J. (1992) · The Lancet · doi:10.1016/0140-6736(92)90865-z · Cited by 2,107
Böger, R. H., Bode-Böger, S. M., Szuba, A., Tsao, P. S., Chan, J. R., Tangphao, O., Blaschke, T. F., & Cooke, J. P. (1998) · Circulation · doi:10.1161/01.cir.98.18.1842 · Cited by 1,181
Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine
Valkonen, V.-P., Päivä, H., Salonen, J. T., Lakka, T. A., Lehtimäki, T., Laakso, J., & Laaksonen, R. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07184-7 · Cited by 562
Asymmetrical Dimethylarginine: The Über Marker?
Cooke, J. P. (2004) · Circulation · doi:10.1161/01.cir.0000126823.07732.d5 · Cited by 396
Böger, R. H. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.10.2842s · Cited by 363
Endogenous nitric oxide synthase inhibitors are responsible for the L‐arginine paradox
Tsikas, D., Böger, R. H., Sandmann, J., Bode-Böger, S. M., & Frölich, J. C. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01686-0 · Cited by 237
N., C., & J., C. (2002) · Diabetologia · doi:10.1007/s00125-002-0975-6 · Cited by 116
Cited by
Rochette, L., Lorin, J., Zeller, M., Guilland, J.-C., Lorgis, L., Cottin, Y., & Vergely, C. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.004 · Cited by 456
Cellular ADMA: Regulation and action
Teerlink, T., Luo, Z., Palm, F., & Wilcox, C. S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.08.002 · Cited by 342
Self-citationCarlström, M., Persson, A. E. G., Larsson, E., Hezel, M., Scheffer, P. G., Teerlink, T., Weitzberg, E., & Lundberg, J. O. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvq366 · Cited by 261
Self-citationvan der Zwan, L. P., Scheffer, P. G., Dekker, J. M., Stehouwer, C. D. A., Heine, R. J., & Teerlink, T. (2011) · Clinical Science · doi:10.1042/cs20100595 · Cited by 40
Self-citationLind, L., Larsson, A., & Teerlink, T. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.07.016 · Cited by 17
Self-citation
Metadata
- Authors
- Siroen, M. P. C., Teerlink, T., Nijveldt, R. J., Prins, H. A., Richir, M. C., & Leeuwen, P. A. M. V.
- Venue
- Annual Review of Nutrition
- Publisher
- Annual Reviews
- Published
- 2006-08-01
- Volume
- 26
- Issue
- 1
- Pages
- 203-228
- ISSN
- 0199-9885 (ISSN-L)
- 1545-4312
- OpenAlex
- W2118067027
- Cited by
- 114
- References
- 8
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Clinical Significance of Asymmetric Dimethylarginine. https://app.cochat.ai/papers/10.1146/annurev.nutr.26.061505.111320
- The paper
- Siroen, M. P. C., Teerlink, T., Nijveldt, R. J., Prins, H. A., Richir, M. C., & Leeuwen, P. A. M. V. (2006). The Clinical Significance of Asymmetric Dimethylarginine. Annual Review of Nutrition. https://doi.org/10.1146/annurev.nutr.26.061505.111320
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.